Literature DB >> 35430641

Dissecting the correlates of N-terminal prohormone brain natriuretic peptide in acute infective endocarditis.

Lorenzo Bertolino1, Maria Paola Ursi1, Domenico Iossa1, Arta Karruli1, Fabiana D'Amico1, Rosa Zampino1,2, Giovanni Dialetto3, Marisa De Feo3, Emanuele Durante-Mangoni4,5.   

Abstract

PURPOSE: To explore the prognostic value and the correlates of NT-proBNP in patients with acute infective endocarditis, a life-threatening disease, with an often unpredictable outcome given by the lack of reliable prognostic parameters.
METHODS: We retrospectively studied 337 patients admitted to our centre between January 1, 2006 and September 30, 2020 with available NT-proBNP level at admission. Our analyses were performed considering NT-proBNP as both a categorical variable, using the median value as the cut-off level, and numerical variable. Study end points were in-hospital mortality, cardiac surgery and 1 year survival.
RESULTS: NT-proBNP was an independent predictor of in-hospital mortality (OR 14.9 [95%C.I. 2.46-90.9]; P = .003). Levels below 2926 pg/mL were highly predictive of a favorable in-hospital outcome (negative predictive value 96.6%). Patients with higher NT-proBNP levels showed a significantly lower survival rate at 1 year follow-up (log-rank P = .005). NT-proBNP was strongly associated with chronic kidney disease (P < .001) and significantly higher in patients with prior chronic heart failure (P = .001). NT-proBNP was tightly related to staphylococcal IE (P = .001) as well as with higher CRP and hs-troponin I (P = 0.023, P < .001, respectively).
CONCLUSION: Our results confirm the remarkable prognostic role of NT-proBNP in patients with IE and provide novel evidences of its multifaceted correlates in this unique clinical setting. Our data strongly support the incorporation of NT-proBNP into the current diagnostic work-up of IE.
© 2022. The Author(s).

Entities:  

Keywords:  Endocarditis; Heart failure; NT-proBNP; Prognostic value

Year:  2022        PMID: 35430641     DOI: 10.1007/s15010-022-01813-y

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   7.455


  29 in total

1.  Biomarkers for prediction of mortality in left-sided infective endocarditis.

Authors:  Rinaldo F Siciliano; Danielle M Gualandro; Marcio Sommer Bittencourt; Milena Paixão; Fabiana Marcondes-Braga; Alexandre de Matos Soeiro; Célia Strunz; Ana Paula Pacanaro; Christian Puelacher; Flavio Tarasoutchi; Salvatore Di Somma; Bruno Caramelli; Mucio Tavares de Oliveira Junior; Alfredo Jose Mansur; Christian Mueller; Antonio Carlos Pereira Barretto; Tânia Mara Varejão Strabelli
Journal:  Int J Infect Dis       Date:  2020-03-10       Impact factor: 3.623

2.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.

Authors:  Matthias Pfisterer; Peter Buser; Hans Rickli; Marc Gutmann; Paul Erne; Peter Rickenbacher; André Vuillomenet; Urs Jeker; Paul Dubach; Hansjürg Beer; Se-Il Yoon; Thomas Suter; Hans H Osterhues; Michael M Schieber; Patrick Hilti; Ruth Schindler; Hans-Peter Brunner-La Rocca
Journal:  JAMA       Date:  2009-01-28       Impact factor: 56.272

3.  B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients.

Authors:  Felix Post; Ludwig S Weilemann; Claudia-Martina Messow; Christoph Sinning; Thomas Münzel
Journal:  Crit Care Med       Date:  2008-11       Impact factor: 7.598

4.  2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).

Authors:  Gilbert Habib; Patrizio Lancellotti; Manuel J Antunes; Maria Grazia Bongiorni; Jean-Paul Casalta; Francesco Del Zotti; Raluca Dulgheru; Gebrine El Khoury; Paola Anna Erba; Bernard Iung; Jose M Miro; Barbara J Mulder; Edyta Plonska-Gosciniak; Susanna Price; Jolien Roos-Hesselink; Ulrika Snygg-Martin; Franck Thuny; Pilar Tornos Mas; Isidre Vilacosta; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

5.  N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.

Authors:  Paulo Bettencourt; Ana Azevedo; Joana Pimenta; Fernando Friões; Susana Ferreira; António Ferreira
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

6.  Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure.

Authors:  Mark E Davis; A Mark Richards; M Gary Nicholls; Timothy G Yandle; Christopher M Frampton; Richard W Troughton
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

Review 7.  A systematic review of biomarkers in the diagnosis of infective endocarditis.

Authors:  Magnus G Snipsøyr; Maja Ludvigsen; Eskild Petersen; Henrik Wiggers; Bent Honoré
Journal:  Int J Cardiol       Date:  2015-09-21       Impact factor: 4.164

8.  Predictors of mortality and adverse events in patients with infective endocarditis: a retrospective real world study in a surgical centre.

Authors:  Valentina Scheggi; Irene Merilli; Rossella Marcucci; Stefano Del Pace; Iacopo Olivotto; Nicola Zoppetti; Nicole Ceschia; Valentina Andrei; Bruno Alterini; Pier Luigi Stefàno; Niccolò Marchionni
Journal:  BMC Cardiovasc Disord       Date:  2021-01-12       Impact factor: 2.298

9.  Prognostic value of pro-adrenomedullin and copeptin in acute infective endocarditis.

Authors:  Rosa Zampino; Domenico Iossa; Maria Paola Ursi; Lorenzo Bertolino; Roberto Andini; Rosa Molaro; Oriana Fabrazzo; Silvia Leonardi; Luigi Atripaldi; Emanuele Durante-Mangoni
Journal:  BMC Infect Dis       Date:  2021-01-07       Impact factor: 3.090

10.  A nationwide cohort study of mortality risk and long-term prognosis in infective endocarditis in Sweden.

Authors:  Anders Ternhag; Agneta Cederström; Anna Törner; Katarina Westling
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.